Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors
Table 1
Characteristics of the patient study population included in the primary analysis.
RT group (n = 41)
Non-RT group (n = 229)
Standardized difference†
Number or mean (SD)†
(%)†
Number or mean (SD)†
(%)†
Before PSW
After PSW
Age (years)
63.61 (8.35)
64.60 (8.30)
0.119
≈0
Sex
Female
24
(59)
158
(69)
0.219
≈0
Male
17
(41)
71
(31)
Residency
Non-northern
22
(54)
160
(70)
0.338
≈0
Northern
19
(46)
69
(30)
Comorbidity
<1
38
(93)
204
(89)
0.125
≈0
≥1
3
(7)
25
(11)
BMI (kg/m2)
25.07 (5.15)
24.01 (3.71)
0.238
≈0
Social-economic status
Minimum wage or lower
9
(22)
70
(31)
0.197
≈0
Higher
32
(78)
159
(69)
Smoking
No
29
(71)
178
(78)
0.161
≈0
Yes
12
(29)
51
(22)
Clinical T-stage
T1–T2
17
(41)
95
(41)
0
≈0
T3–T4
24
(59)
134
(59)
Clinical N-stage
N0–N2
11
(27)
49
(21)
0
≈0
N3
30
(73)
180
(79)
Tumor size (mm)
45.71 (19.23)
42.97 (20.74)
0.137
≈0
ECOG PS
0-1
36
(88)
212
(93)
0.161
≈0
2
5
(12)
17
(7)
BMI, body mass index; ECOG PS, eastern cooperative oncology group performance status; PSW, propensity score weighting; RT, radiotherapy; SD, standard deviation. †Rounded.
